Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

Baldeep Wirk, Timothy S. Fenske, Mehdi Hamadani, Mei Jie Zhang, Zhen Huan Hu, Görgün Akpek, Mahmoud D. Aljurf, Philippe Armand, Ernesto Ayala, Veronika Bachanova, Brian Bolwell, Mitchell S. Cairo, Amanda Cashen, Yi Bin Chen, Luciano J. Costa, Shatha Farhan, César O. Freytes, James L. Gajewski, John Gibson, Gregory A. HaleLeona A. Holmberg, Jack W. Hsu, David J. Inwards, Rummurti T. Kamble, Dipnarine Maharaj, Richard T. Maziarz, Reinhold Munker, Rajneesh Nath, Nishitha M. Reddy, Craig B. Reeder, David A. Rizzieri, Craig S. Sauter, Bipin N. Savani, Harry C. Schouten, Anna Sureda, Julie M. Vose, Edmund K. Waller, Peter H. Wiernik, Robert Peter Gale, Linda J. Burns, Wael Saber

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in diffuse large B cell lymphoma transformed from follicular lymphoma. We analyzed transplantation outcomes in 141 subjects with biopsy-proven diffuse large B-cell lymphoma transformed from follicular lymphoma reported to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups were identified: autologous HCT (auto-HCT; n = 108) and allogeneic HCT (allo-HCT; n = 33). Fewer auto-HCTs were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was associated with a 1-year nonrelapse mortality (NRM) of 8% (95% confidence interval [CI], 4% to 14%), 5-year progression-free survival of 35% (95% CI, 26% to 45%), and 5-year overall survival of 50% (95% CI, 40% to 59%). In contrast, allo-HCT was associated with a 1-year NRM of 41% (95% CI, 23% to 58%), 5-year progression-free survival of 18% (95% CI, 6% to 35%), and 5-year overall survival of 22% (95% CI, 8% to 41%). Auto-HCT for transformed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of allo-HCT offset any benefit that might be associated with this transplantation modality.

Original languageEnglish (US)
Pages (from-to)951-959
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number7
DOIs
StatePublished - Jul 2014

Bibliographical note

Funding Information:
Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Cooperative Agreement U24 CA076518 from the National Cancer Institute (NCI) , the National Heart, Lung and Blood Institute (NHLBI) , and the National Institute of Allergy and Infectious Diseases ; Grant/Cooperative Agreement U10 HL069294 from the NHLBI and NCI ; Contract HHSH250201200016C with Health Resources and Services Administration; Grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research; and grants from Allos Therapeutics, Amgen, anonymous donation to the Medical College of Wisconsin, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Celgene, Fresenius-Biotech North America, Gamida Cell Teva Joint Venture, Genentech, Gentium, Genzyme, GlaxoSmithKline, HistoGenetics, Kiadis Pharma, Leukemia & Lymphoma Society, Medical College of Wisconsin, Merck & Co, Millennium: Takeda Oncology, Milliman USA, Miltenyi Biotec, National Marrow Donor Program, Onyx Pharmaceuticals, Optum Healthcare Solutions, Osiris Therapeutics, Otsuka America Pharmaceutical, Remedy Informatics, Sanofi US, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, StemCyte, Stemsoft Software, Swedish Orphan Biovitrum, Tarix Pharmaceuticals, TerumoBCT, Teva Neuroscience, Therakos, and Wellpoint. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, Department of the Navy, Department of Defense, or any other agency of the US Government.

Keywords

  • Transformed follicular lymphoma
  • Transplant

Fingerprint Dive into the research topics of 'Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma'. Together they form a unique fingerprint.

Cite this